Amsbio has expanded its range of iPSC Differentiation Kits that provide fast and flexible generation of specific cell types without sacrificing cell purity.

New to market - Quick-Glia™ product line consist of human induced pluripotent stem cell derived glial cells designed for rapid, reliable, and reproducible research in neurobiology, drug discovery, and neurodegeneration. Offering a reproducible, and scalable solution, these kits enable the conversion of iPSCs into functional neurons in just 1-2 weeks. Designed for ease of use, they provide a streamlined workflow for disease modelling, drug screening, and neurobiology applications.

Quick-Glia™ Astrocyte – SeV kits facilitate the differentiation of human pluripotent stem cells into astrocytes using Sendai virus technology through a streamlined and reproducible workflow. These new easy-to-use kits offer rapid differentiation to reproducibly produce highly pure populations of astrocyte cells. Neuroscience researchers are intensely interested in astrocytes because they are now recognized as active, dynamic regulators of brain function. Characterization of iPSC-derived astrocytes is crucial to ensure their utility in research. Employing astrocyte markers, researchers can confirm the identity and purity of these cells.

There are also Quick-Glia™ human iPSC-derived microglia. These are high purity, off-the-shelf microglia that provide a consistent, biologically relevant in vitro model for studying human microglial biology and disease. These cryopreserved, ready-to-use iPSC-derived microglia mature rapidly and deliver reproducible performance for drug discovery, toxicity screening, and neurodegenerative disease research. The associated microglia maintenance media is also available and offered separately.

For further information please visit https://www.amsbio.com/stem-cell-synergy-solution-differentiate/ipsc-differentiation-kits/#mg or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected]..

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America, and wider international markets. With in depth expertise in advanced cell culture, 3D cell models, and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development, and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem call platform combining StemFit™ media, iMatrix™ recombinant laminins, and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognized for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech, and pharmaceutical markets to translate innovation from bench to bedside.